Saad Z. Usmani, MD

    Saad Z. Usmani, MD

    Director of Plasma Cell Disorders Program, director of clinical research in hematologic malignancies
    • Is MRD Testing Worthwhile in Myeloma? Friday, June 16th, 2017

      With the clinically effective treatment regimens now available for myeloma, more patients can achieve deep and sustained responses. The ability to measure minimal residual disease (MRD) during and after treatment has the potential to help guide treatment decisions and predict patients’ likelihood of relapse, but is MRD monitoring ready to be used in routine clinical [...]

    SHARE